Current Ketamine News and Events | Page 4

Current Ketamine News and Events, Ketamine News Articles.
Sort By: Most Relevant | Most Viewed
Page 4 of 5 | 198 Results
'Swingers' multiple drug use heightens risk of sexually transmitted diseases
People who engage in heterosexual group sex and partner swapping are increasing their risk of catching sexually transmitted diseases if they engage in multiple drug use, says a study published online in the journal Sexually Transmitted Infections. (2014-10-23)

Rapid agent restores pleasure-seeking ahead of other antidepressant action
A drug being studied as a fast-acting mood-lifter restored pleasure-seeking behavior independent of -- and ahead of -- its other antidepressant effectsWithin 40 minutes after a single infusion of ketamine, treatment-resistant depressed bipolar disorder patients experienced a reversal of a key symptom -- loss of interest in pleasurable activities -- which lasted up to 14 days. Brain scans traced the agent's action to boosted activity in areas at the front and deep in the right hemisphere of the brain. (2014-10-20)

The Lancet HIV: High rates of recreational drug use among HIV-positive gay and bisexual men in the UK strongly linked with condomless sex
New research published in The Lancet HIV shows that polydrug use is common among HIV-positive men who have sex with men and is strongly linked to sex without a condom. (2014-09-07)

The bit of your brain that signals how bad things could be
An evolutionarily ancient and tiny part of the brain tracks expectations about nasty events, finds new UCL research. The study, published in Proceedings of the National Academy of Sciences, demonstrates for the first time that the human habenula, half the size of a pea, tracks predictions about negative events, like painful electric shocks, suggesting a role in learning from bad experiences. (2014-07-28)

Ketamine can be a wonder drug for ER patients and their physicians
For critically ill patients arriving at the emergency department, the drug ketamine can safely provide analgesia, sedation and amnesia for rapid, life-saving intubation, despite decades-old studies that suggested it raised intracranial pressure. The results of a systematic review of 10 recent studies of what many emergency physicians regard as a 'wonder drug' are published online in Annals of Emergency Medicine. (2014-07-23)

Researchers identify new compound to treat depression
Researchers have identified a compound, hydroxynorketamine, that may treat symptoms of depression just as effectively and rapidly as ketamine, without the unwanted side effects associated with the psychoactive drug, according to a study in the July issue of Anesthesiology, the official medical journal of the American Society of Anesthesiologists. Interestingly, use of HNK may also serve as a future therapeutic approach for treating neurodegenerative disorders such as Alzheimer's and Parkinson's diseases, the authors note. (2014-06-17)

Researchers uncover new insights into developing rapid-acting antidepressant for treatment-resistant depression
UT Southwestern Medical Center researchers have generated fresh insights that could aid in the development of rapid-acting antidepressants for treatment-resistant depression. (2014-06-12)

Intranasal ketamine confers rapid antidepressant effect in depression
A research team from the Icahn School of Medicine at Mount Sinai published the first controlled evidence showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect -- within 24 hours -- and was well tolerated in patients with treatment-resistant major depressive disorder. (2014-04-08)

First UK study of ketamine for people with severe depression
The first UK study of the use of ketamine intravenous infusions in people with treatment-resistant depression has been carried out in an NHS clinic by researchers at Oxford Health NHS Foundation Trust and the University of Oxford. (2014-04-02)

New depression treatments reported
New insights into the physiological causes of depression are leading to treatments beyond common antidepressants such as Prozac and Zoloft, researchers are reporting in the journal Current Psychiatry. (2014-02-14)

Ketamine acts as antidepressant by boosting serotonin
New research from the RIKEN Center for Life Science Technologies in Japan demonstrates using PET imaging studies on macaque monkeys that ketamine increases the activity of serotoninergic neurons in the brain areas regulating motivation. The researchers conclude that ketamine's action on serotonin, often dubbed the (2014-01-07)

Drug residues detected in Swedish sewage water
Chemists at UmeƄ University in Sweden have been able to trace narcotics substances and prescription drugs in measurements of wastewater from 33 Swedish sewage treatment plants. Cocaine, amphetamine, and methamphetamine, in measurable concentrations, were found in a total of half of the locations. (2013-12-17)

mTOR: A key brain signaling mechanism for rapidly acting antidepressants
Two years ago, mammalian target of rapamycin or mTOR, a signaling protein, was identified as a key mediator of the antidepressant effects of ketamine, the first rapidly acting antidepressant medication to be identified. (2013-11-19)

Would an 'anti-ketamine' also treat depression?
Thirteen years ago, an article in this journal first reported that the anesthetic medication, ketamine, showed evidence of producing rapid antidepressant effects in depressed patients who had not responded to prior treatments. Ketamine works by blocking one of the targets for the neurotransmitter glutamate in the brain, the N-methyl-D-aspartate glutamate receptor. (2013-11-18)

A potential new class of fast-acting antidepressant
More than one in 10 Americans take antidepressants, but these medications can take weeks -- and for some patients, months -- before they begin to alleviate symptoms. Now, scientists from the University of Chicago have discovered that selectively blocking a serotonin receptor subtype induces fast-acting antidepressant effects in mice, indicating a potential new class of therapeutics for depression. The work was published Oct. 29 in Molecular Psychiatry. (2013-10-29)

Towards a real understanding of depression
This Neuropsychoanalysis Association hosted interdisciplinary conference for researchers and clinicians, (2013-10-23)

Salk researchers develop new model to study schizophrenia and other neurological conditions
Schizophrenia is one of the most devastating neurological conditions, with only 30 percent of sufferers ever experiencing full recovery. While current medications can control most psychotic symptoms, their side effects can leave individuals so severely impaired that the disease ranks among the top 10 causes of disability in developed countries. (2013-08-29)

Researcher awarded $1.8 million grant to study gender differences in antidepressant effects
A Florida State University College of Medicine researcher is investigating why ketamine, used as an antidepressant for the last decade, requires a higher dosage to improve depression in males. (2013-08-15)

Shocking: Surgical anesthetic appears to treat drug-resistant depression
Although electroconvulsive therapy has long been considered the most effective treatment of medication-resistant depression, millions of people who might benefit don't take advantage of it because of the treatment's side effects and public misperception of the procedure. (2013-07-27)

Ketamine as anesthetics can damage children's learning and memory ability
Recent studies have found that anesthesia drugs have neurotoxicity on the developing neurons, causing learning and memory disorders and behavioral abnormalities. Ketamine is commonly used in pediatric anesthesia. A clinical retrospective study found that children below 3 years old who receive a long time surgery, or because of surgery require ketamine repeatedly will exhibit the performance of school-age learning and memory disorders and behavioral abnormalities. (2013-07-18)

Anesthetic for depression? Mayo Clinic study finds low-dose ketamine effective
Low-dose intravenous infusions of ketamine, a general anesthetic used in minor surgeries, given over a long period are an effective treatment for depression, Mayo Clinic researchers found. The study is published in the Journal of Psychopharmacology. (2013-06-04)

Ketamine cousin rapidly lifts depression without side effects
GLYX-13, a molecular cousin to ketamine, induces similar antidepressant results without the street drug side effects, reported a study funded by the National Institute of Mental Health that was published last month in Neuropsychopharmacology. (2013-05-30)

Ketamine shows significant therapeutic benefit in people with treatment-resistant depression
Patients with treatment-resistant major depression saw dramatic improvement in their illness after treatment with ketamine, an anesthetic, according to the largest ketamine clinical trial to date led by researchers from the Icahn School of Medicine at Mount Sinai. The antidepressant benefits of ketamine were seen within 24 hours, whereas traditional antidepressants can take days or weeks to demonstrate a reduction in depression. (2013-05-18)

Human cognition depends upon slow-firing neurons
Good mental health and clear thinking depend upon our ability to store and manipulate thoughts on a sort of (2013-02-20)

Imaging biomarker predicts response to rapid antidepressant
A boost of activity at the back of the brain while processing emotional information predicted depressed patients' responses to an experimental rapid-acting antidepressant. The potential neuroimaging biomarker may eventually help to personalize treatment selection by revealing brain-based differences between patients. Scopolamine can lift depression in many, but not all, patients within a few days. The study found that the more dysfunctional a patient's acetylcholine chemical messenger system, the better they responded to the drug. (2013-02-04)

Brain & Behavior Research Foundation awards $1.5M in Distinguished Investigator Grants
The Brain & Behavior Research Foundation announced the latest 15 recipients of its highly-competitive NARSAD Distinguished Investigator Grants of up to $100,000 each for promising new research on mental illness, including depression, schizophrenia, bipolar disorder, autism, attention-deficit hyperactivity disorder and anxiety disorders such as post-traumatic stress disorder and obsessive-compulsive disorder. The Foundation Scientific Council reviewed 225 applications and selected the cutting-edge ideas with the greatest potential for mental illness breakthroughs and discoveries. (2013-01-14)

Countering brain chemical could prevent suicides
Researchers have found the first proof that a chemical in the brain called glutamate is linked to suicidal behavior, offering new hope for efforts to prevent people from taking their own lives. (2012-12-13)

Experimental agent briefly eases depression rapidly in test
A drug that works through the same brain mechanism as the fast-acting antidepressant ketamine briefly improved treatment-resistant patients' depression symptoms in minutes, with minimal untoward side effects, in a clinical trial. The experimental agent, called AZD6765, acts through the brain's glutamate chemical messenger system. The findings serve as a proof of concept that targeting this system holds promise for development of a new generation of rapid antidepressants with fewer side effects than ketamine. (2012-12-12)

ACNP: Novel NMDA receptor modulator significantly reduces depression scores within hours
Naurex reports Phase 2 data at ACNP showing a single administration of novel NMDA receptor modulator GLYX-13 produced statistically significant reductions in depression scores within 24 hours in subjects who had failed prior treatment. The effect size, a measure of efficacy, observed at 24 hours and seven days, was nearly double that seen with other antidepressants after weeks of repeated dosing. GLYX-13 was free of the schizophrenia-like effects seen with other NMDAR modulators like ketamine. (2012-12-06)

New antidepressant acts very rapidly and is long lasting
A first-of-its-kind antidepressant drug discovered by a Northwestern University professor and now tested on adults who have failed other antidepressant therapies has been shown to alleviate symptoms within hours, have good safety and produce positive effects that last for about seven days from a single dose. The novel therapeutic targets brain receptors responsible for learning and memory -- a very different approach from existing antidepressants. The new drug could be helpful in treating other neurological conditions. (2012-12-06)

Glutamate neurotransmission system may be involved with depression risk
Researchers using a new approach to identifying genes associated with depression have found that variants in a group of genes involved in transmission of signals by the neurotransmitter glutamate appear to increase the risk of depression. (2012-11-13)

How ketamine defeats chronic depression
Many chronically depressed and treatment-resistant patients experience immediate relief from symptoms after taking small amounts of the drug ketamine. For a decade, scientists have been trying to explain the observation first made at Yale University. (2012-10-04)

Drug reverses abnormal brain function in rett syndrome mice
A promising study out today in the prestigious Journal of Neurosciences showed that in a mouse model of Rett syndrome, researchers were able to reverse abnormalities in brain activity and improve neurological function by treating the animals with an FDA-approved anesthesia drug, ketamine. Rett syndrome is among the most severe autism-related disorders, affecting about one in 10,000 female births per year, with no effective treatments available. (2012-10-03)

Brain signal IDs responders to fast-acting antidepressant
Scientists have discovered a biological marker that may help to identify which depressed patients will respond to an experimental, rapid-acting antidepressant. The brain signal, detectable by noninvasive imaging, also holds clues to the agent's underlying mechanism, which are vital for drug development. The signal is among the latest of several such markers recently uncovered, including factors detectable in blood, genetic markers, and a sleep-specific brain wave. (2012-08-06)

The big sleep
How do you anesthetize a hippopotamus? Difficulties are posed not only by the undesirability of approaching waking animals but also by hippos' unique skin morphology and by the animals' sensitivity to standard anesthetic methods. A new procedure is now described by the group of Chris Walzer at the Research Institute of Wildlife Ecology of the University of Veterinary Medicine, Vienna and published in the current issue of the Journal of the American Veterinary Medical Association. (2012-07-03)

Ketamine improved bipolar depression within minutes
Bipolar disorder is a serious and debilitating condition where individuals experience severe swings in mood between mania and depression. The episodes of low or elevated mood can last days or months, and the risk of suicide is high. (2012-05-30)

Internet and new drugs: A challenge for public health
During 2010 41 new psychoactive substances were officially notified to the European Union, nearly double than during the previous year, most of which are available on Internet. One of these new abused drugs is methoxetamine, sold as a (2012-05-08)

Treatments to reduce anesthesia-induced injury in children show promise in animal studies
Recent clinical studies have shown that general anesthesia can be harmful to infants, presenting a dilemma for both doctors and parents. But new research at Wake Forest Baptist Medical Center may point the way to treatment options that protect very young children against the adverse effects of anesthesia. (2012-03-28)

Summary of evidence shows most patients need several sequential treatment steps for remission of major depression
Major depressive disorder is a major public health problem that affects seven percent of the population during any 12-month period and affects around one in six people throughout their lifetime. A Seminar published Online First by the Lancet reviews recent developments relating to this seriously disabling condition, and concludes that most patients need several sequential treatment steps for remission of their major depression. (2011-12-19)

A new line of defense against sexual assault
Professor Fernando Patolsky and Dr. Michael Ioffe of Tel Aviv University have developed an easy-to-use sensor that, when dipped into a cocktail, will instantly detect the presence of a date rape drug. When ready for commercial purchase in just a few years, the sensor will be lightweight and discreet, easily transportable in a pocket or purse. (2011-08-09)

Page 4 of 5 | 198 Results
   First   Previous   Next      Last is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to